Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer

scientific article published on 01 January 1998

Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1035158601
P356DOI10.1023/A:1006195815320
P698PubMed publication ID10360605

P2093author name stringS Murthy
P Elson
D McLain
R Bukowski
G T Budd
D Peereboom
K Rajagopalan
T Olencki
P2860cites workCancer statistics, 1998.Q34065873
Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trialQ34683968
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancerQ41072693
Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trialQ41273703
Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancerQ43739019
Phase II study of 5'-DFUR treatment of the bladder and prostatic cancerQ46260324
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.Q53622998
The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostateQ67779831
Circadian variation of fluoropyrimidine catabolic enzymes in rat liver: possible relevance to 5-fluorodeoxyuridine chemotherapyQ68297244
Determination of the therapeutic index of floxuridine by its circadian infusion patternQ68410401
Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusQ68689282
Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinomaQ70058111
Weekly doxorubicin in endocrine-refractory carcinoma of the prostateQ71186859
Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancerQ72078080
Phase I study of continuous venous infusion of floxuridine (5-FUDR) chemotherapyQ72791795
A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center StudyQ72910588
THE PHYSIOLOGIC DISPOSITION OF 5-FLUOROURACIL AND 5-FLUORO-2'-DEOXYURIDINE IN MANQ76959399
P433issue3
P921main subjectprostate cancerQ181257
floxuridineQ5462356
phase II clinical trialQ42824440
P304page(s)255-258
P577publication date1998-01-01
P1433published inInvestigational New DrugsQ2312231
P1476titlePhase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer
P478volume16

Reverse relations

cites work (P2860)
Q34155429Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?
Q35145701Current strategies in the management of hormone refractory prostate cancer
Q28279056Systematic review of agents for the management of gastrointestinal mucositis in cancer patients
Q28077467WOMEN IN CANCER THEMATIC REVIEW: Circadian rhythmicity and the influence of 'clock' genes on prostate cancer

Search more.